Join the Zephyr® Valve Quiz

Yes! This is correct!



You have all answers correct

One last step…

Please tick “yes” so we can stay connected and send you information and updates on our therapy and events.

I hereby agree that Pulmonx International Sàrl and its affiliates may contact me via email about treatment methods, further information material, invitation to upcoming events or surveys and process my personal data for the purposes stated above. I can withdraw my consent anytime by clicking on the opt-out link provided in the emails.*

* Mandatory Field


1 Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151‒1164.
2 Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2023.
3 Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L & Briault, A. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med, 2017;196(12), 1535-1543.
4 Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med, 2016;194(9), 1073-1082, and data on file at Pulmonx.
5 Klooster, K, ten Hacken, NH, Hartman, JE, Kerstjens, HA, van Rikxoort, EM & Slebos, DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med, 2015;373(24), 2325-2335.
6 Hartman, Jorine E et al. Respir Med. 2022; 196:106825. doi:10.1016/j.rmed.2022.106825.
7 Van der Molen MC et al. Am J Respir Crit Care Med. 2022; 206 (6): 704–711.
8 From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017. Available from:
9 From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020. Available from:
10 NICE (National Institute for Health and Care Excellence) Final Guidance on Endobronchial valve insertion to reduce lung volume in emphysema (, accessed Dec. 20, 2017.

Important Safety Information: The Zephyr® Endobronchial Valve is an implantable bronchial valve intended to control airflow in order to improve lung functions in patients with hyperinflation associated with severe emphysema with little to no collateral ventilation, and/or to reduce air leaks. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; Evidence of active pulmonary infection; Patients with known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); Patients with known allergies to silicone; Patients who have not quit smoking. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

©2024 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation and its affiliates. EUR-EN-1988-v1 Pulmonx Event Quiz August 2023